ANBC INC (SYUP) Fair Value & Analysis

Healthcare · US · Market cap $15.9K

A solid business, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Our model range runs from $0.0002 (bear) to $0.0002 (bull), base $0.0002. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 53/100 (solid quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range $0.0001 – $0.2500 · the $0.0002 price screens below the $0.0002 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

ANBC INC (SYUP) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Trailing-twelve-month revenue stands at $50.9K. It earns a return on equity of -23.9%. Fundamentals as of Aug 13, 2026

The share trades about 33% below its 52-week high and 100% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, SYUP screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings ($0.0006) versus Multiples ($0.0001). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

ANBC, INC. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China.

Full company description

ANBC, INC. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion. It also offers Ban-lan-gen that relieves cold and flu symptoms; Gan-mao-qing-re that relieves minor body aches and pains, and reduces fever; Huang-dan-yin-chen used in the treatment for jaundice infection hepatitis; and Liu-shen-qu for treatment of vomitings and dysentery. It offers its products to distributors on a wholesale basis. ANBC, INC. was formerly known as Shanghai Yutong Pharma, Inc. and changed its name to ANBC, INC. in August 2016. The company was incorporated in 2003 and is based in Shanghai, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2006 – FY2017 · reported fiscal years

ANBC INC reported revenue of $3.2M in FY2017 versus $312K in FY2006, a compound +23.4%/yr. Reported net income was $1.3M in FY2017.

Watch SYUP: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.